The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think
January 07 2021 - 8:00AM
InvestorsHub NewsWire
New York, NY -- January 7,
2021 -- InvestorsHub NewsWire -- Traders News
Source, a leading independent equity research and corporate
access firm focused on small cap growth companies issues new
biotech stock reports and resources for timing biotech
trades.
Amarin Corporation plc
(NASDAQ:
AMRN) only has one drug, Vascepa. It's a medication
that reduces strokes and heart attacks. Some say that Vascepa is
one of the most important developments in the prevention and
treatment of cardiovascular disease since
statins.
While Vascepa is an approved drug,
sold in the USA, ten months ago an American judge (the company is
based in Ireland) vacated some Amarin patents, opening the door for
generic competition. AMRN is still waiting for Vascepa approval in
the EU and anticipates a patent protected rollout of the product
there. Estimates for peak sales in the EU are at $2.8
billion.
Three months ago,
Northwest Biotherapeutics, Inc. (OTCQB:
NWBO) announced that the database for the Phase III
trial of DCVax®-L for Gliobastoma has been locked. The phase III
trial had been ongoing for 14 years and now independent
statisticians are tallying up the results. DCVax®-L is the only
product of consequence for NWBO, so the company’s future rides on
the clinicals results. On September 1, 2020 NWBO acquired
Flaskworks, a company that has developed and automated the
manufacturing of cell therapy products such as
DCVax®.
There are parties on both sides of
the NWBO and DCVax®-L prospects discussion with valid points to
make. Investors are examining the bullish and bearish cases to
determine which one best fits their investing
agenda.
See Traders News Source
FDA / PDUFA research resources for Biotech investors READ
MORE
Copy and paste to browser
may be required https://tradersnewssource.com/fda-calendar/
CytoDyn Inc. (OTCQB:
CYDY) is a late-stage biotechnology company developing
Vyrologix™, a CCR5 antagonist with the potential for multiple
therapeutic indications. The company has been studying the impact
of Vyrologix on Covid 19 patients. Nicholas J. Agresti, M.D. has
treated four patients, on ventilators, with great success and
written a paper detailing the results. The paper has been accepted
for publication in the Journal of Translational
Autoimmunity.
Nader Pourhassan, Ph.D., President
and Chief Executive Officer of CytoDyn, commented, “We are
appreciative of Dr. Agresti’s work and view his publication as a
validation of Vyrologix as an important potential therapeutic in
the treatment of seriously ill COVID-19 patients.
Enzolytics Inc. (OTCPINK:
ENZC) and BioClonetics Immunotherapeutics, Inc.
entered a non-binding letter of intent to combine the two entities
and pursue our joint mission to create therapeutics that are
effective and affordable for the treatment of some of the most
infectious and deadly diseases in the world, including HIV and the
Coronavirus.
According to a December letter to
shareholders:” Our new lab is being opened on the campus of Texas
A&M University in the University's Institute for Preclinical
Studies. Here we will expand our development capabilities for the
production of additional monoclonal antibodies targeting immutable
sites on the HIV and SARS-CoV-2 viruses. We have engaged an
artificial intelligence (AI) and genetics and molecular biology
data science team to curate the thousands of isolates (strains) now
known as existing in both the HIV virus and the SARS-CoV-2 virus.
This process will allow us to identify conserved, immutable targets
against which monoclonal antibodies are to be
produced.”
Our FDA Approval Calendar
and other biotech stock resources READ
MORE
Copy and paste to browser
may be required https://tradersnewssource.com/fda-calendar/
DISCLOSURE
Traders News Source LLC (TNS) produces regular
sponsored and non-sponsored reports, articles, stock market blogs,
and popular investment newsletters covering small and micro-cap
equity markets. TNS has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE, NASDAQ, and OTC exchanges. The
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
TNS
LLC has not been compensated; directly or indirectly; for producing
or publishing this document.
PRESS RELEASE
PROCEDURES
The
non-sponsored content contained herein has been prepared by a
writer (the "Author") and is fact checked and reviewed by a
third-party research service company (the "Reviewer") represented
by a chartered financial analyst, for further information on
analyst credentials, please email editor@tradersnewssource.com. TNS
LLC provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written, and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author per
the procedures outlined by TNS. TNS is not entitled to veto or
interfere in the application of such procedures by the third-party
research service company to the articles, documents, or reports.
Unless otherwise noted, any content outside of this document has no
association with the Author or the Reviewer in any
way.
NO
WARRANTY
TNS, the Author, and the Reviewer are not
responsible for any error which may be occasioned at the time of
printing of this document or any error, mistake, or shortcoming. No
liability is accepted whatsoever for any direct, indirect, or
consequential loss arising from the use of this document. TNS, the
Author, and the Reviewer expressly disclaim any fiduciary
responsibility or liability for any consequences, financial or
otherwise arising from any reliance placed on the information in
this document. Additionally, TNS, the Author, and the Reviewer do
not (1) guarantee the accuracy, timeliness, completeness, or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
NOT
AN OFFERING
This document is not intended as an offering,
recommendation, or a solicitation of an offer to buy or sell the
securities mentioned or discussed and is to be used for
informational purposes only. Please read all associated disclosures
and disclaimers in full before investing. Neither TNS nor any party
affiliated with us is a registered investment adviser or
broker-dealer with any agency or in any jurisdiction whatsoever. To
download our report(s), read our disclosures, or for more
information, visit http://www.tradersnewssource.com.
For
any questions, inquiries, or comments reach out to us directly. If
you're a company we are covering and wish to no longer be featured
on our coverage list, contact us via email at:
editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are
registered trademarks owned by CFA
Institute.
CONTACT:
editor@tradersnewssource.com
SOURCE: Traders News
Source
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2023 to Aug 2024